Targeting heat shock response to sensitize cancer cells to proteasome and Hsp90 inhibitors

Cancer Research

Volumn 66, Issue 3, 2006, Pages 1783-1791

  Zaarur, Nava ^a   Gabai, Vladimir L ^a   Porco Jr , John A ^b   Calderwood, Stuart ^c   Sherman, Michael Y ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Boston University   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DEHYDROEMETINE; EMETINE; EMUNIN; HEAT SHOCK PROTEIN 90 INHIBITOR; HEAT SHOCK TRANSCRIPTION FACTOR 1; ISOCEPHAELINE; NCS 10105; NCS 113238; NCS 118072; NCS 129414; NCS 131547; NCS 131548; NCS 134754; NCS 134757; NCS 134758; NCS 134759; NCS 32944; NZ 28; NZ 50; NZ 54; NZ 60; NZ 61; NZ 62; NZ 71; NZ 72; PROTEASOME INHIBITOR; TUBULOSINE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; DRUG INHIBITION; DRUG STRUCTURE; HEAT SHOCK RESPONSE; IMMUNOBLOTTING; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; TOXICITY; TREATMENT RESPONSE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; EMETINE; HEAT-SHOCK RESPONSE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 32944454483     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-3692     Document Type: Article

References (25)

1. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004;5:417-21.
2. Mitsiades N, Mitsiades CS, Poulaki V, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. PNAS 2002;99:14374-9.
3. Chauhan D, Hideshima T, Mitsiades C, Richardson P, Anderson KC. Proteasome inhibitor therapy in multiple myeloma. Mol Cancer Ther 2005;4:686-92.
4. Neckers L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 2002;8:555-61.
5. Hostein I, Robertson D, DiStefano F, Workman P. Andrew Clarke P. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17- demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res 2001;61:4003-9.
6. Fujita N, Sato S, Ishida A, Tsuruo T. Involvement of Hsp90 in signaling and stability of 3-phosphoinositide-dependent kinase-1. J Biol Chem 2002;277:10346-53.
7. Broemer M, Krappmann D, Scheidereit C. Requirement of Hsp90 activity for IκB kinase (IKK) biosynthesis and for constitutive and inducible IKK and NF-κB activation. Oncogene 2004;23:5378-86.
8. Blagosklonny MV. Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs. Leukemia 2002;16:455-62.
9. Gabai VL, Sherman MY. Hsp72 and cell signalling. In: P.A. Henderson B, editors. Molecular chaperones and cell signaling. Cambridge: Cambridge University Press; 2005. p. 144-59.
10. Mosser D, Morimoto RI. Molecular chaperones and the stress of oncogenesis. Oncogene 2004;23:2907-18.
11. Ciocca D, Calderwood SK. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 2005;10:86-103.
12. Beere HM. 'The stress of dying': the role of heat shock proteins in the regulation of apoptosis. J Cell Sci 2004;117:2641-51.
13. Chauhan D, Li G, Shringarpure R, et al. Blockade of hsp27 overcomes bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Res 2003;63:6174-7.
14. Gabai VL, Budagova KR, Sherman MY. Increased expression of the major heat shock protein Hsp72 in human prostate carcinoma cells is dispensable for their viability but confers resistance to a variety of anticancer agents. Oncogene 2005;24:3328-38.
15. Meriin AB, Yaglom JA, Gabai VL, Mosser DD, Zon L, Sherman MY. Protein damaging stresses activate JNK via inhibition of its phosphatase: a novel pathway controlled by Hsp72. Mol Cell Biol 1999;19:2547-55.
16. Bagatell R, Paine-Murrieta GD, Taylor CW, et al. Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents. Clin Cancer Res 2000;6:3312-8.
17. Asea A, Ara G, Teicher BA, Stevenson MA, Calderwood SK. Effects of the flavonoid drug quercetin on the response of human prostate tumors to hyperthermia in vitro and in vivo. Int J Hyperthermia 2001;17:347-56.
18. Chen C, Xie Y, Stevenson MA, Auron PE, Calderwood SK. Heat shock factor 1 represses ras-induced transcriptional activation of the c-fos gene. J Biol Chem 1997;272:26803-6.
19. McMillan DR, Xiao X Shao L, Graves K, Benjamin IJ. Targeted disruption of heat shock transcription factor 1 abolishes thermotolerance and protection against heat-inducible apoptosis. J Biol Chem 1998;273:7523-8.
20. Wu G, Osada M, Quo Z, et al. {Delta}Np63{alpha} upregulates the hsp70 gene in human cancer. Cancer Res 2005;65:758-66.
21. Hosokawa N, Hirayoshi K, Kudo H, et al. Inhibition of the activation of heat shock factor in vivo and in vitro by flavonoids. Mol Cell Biol 1992;12:3490-8.
22. Akagawa H, Takano Y, Ishii A, et al. Stresgenin B, an inhibitor of heat-induced heat shock protein gene expression, produced by Streptomyces sp. AS-9. J Antibiot 1999;52:960-70.
23. Ohnishi K, Takahashi A, Yokota S, Ohnishi T. Effects of a heat shock protein inhibitor KNK437 on heat sensitivity and heat tolerance in human squamous cell carcinoma cell lines differing in p53 status. Int J Radiat Biol 2004;80:607-14.
24. Khaleque M, Bharti A, Sawyer D, et al. Induction of heat shock proteins by heregulin β1 leads to protection from apoptosis and anchorage- independent growth. Oncogene 2005;24:6564-73.
25. Pettit GRG, Kirti S. Antineoplastic agents. XX. Structural biochemistry. VII. 2′(N′-bis(2-chloroethyl)glycyltryptophyl)emetine and related peptides. Can J Chem 1967;45:1561-6.